case_images: PMC6594310_01
case_images: PET/CT image prior to immunotherapy.
case_images: CRIONM2019-2305315.001.jpg
case_images: PMC6594310_01_CRIONM2019-2305315.001.jpg
case_images: fig1
case_images: On first surveillance PET/CT, at 12 weeks postconcurrent chemoradiation treatment, she was found to have PET-avid hepatic and bone lesions (Figure 1).
case_images: Biopsy of metastatic lesion involving the portacaval lymph node.
case_images: CRIONM2019-2305315.002.jpg
case_images: PMC6594310_01_CRIONM2019-2305315.002.jpg
case_images: fig2
case_images: A CT-guided portacaval lymph node biopsy confirmed a metastatic disease (Figure 2).
case_images: PET/CT after 4 cycles of Pembrolizumab.
case_images: CRIONM2019-2305315.003.jpg
case_images: PMC6594310_01_CRIONM2019-2305315.003.jpg
case_images: fig3
case_images: Pembrolizumab monotherapy resulted in a near complete resolution of her hepatic metastasis and complete metabolic resolution of the left parotid mass, cervical adenopathy, and skeletal lesions on PET/CT following four cycles (Figure 3).